Feature Paper in Section "Cancer Epidemiology and Prevention" in 2022–2023

Guest Editors:

Prof. Dr. Roger Anderson
1. Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
2. Cancer Center, University of Virginia, Charlottesville, VA 22908, USA

Dr. Paweł Koczkodaj
Cancer Epidemiology and Primary Prevention Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland

Deadline for manuscript submissions:
closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

Cancer prevention and cancer epidemiology are among the most crucial elements of oncology. Primary and secondary cancer prevention give efficient tools aiming at reducing risk factor exposure, as well as allowing us to detect cancer at very early stage. It has been estimated that at least 50% of all cancer cases could be prevented if we follow healthy lifestyle recommendations. Moreover, cancer epidemiology gives us a broad picture on how efficient cancer prevention is and where further improvement is needed. Thanks to cancer epidemiology, we can also observe changes in health behaviors, cancer incidence, and treatment efficacy as a result of policy.

We would like to invite you to submit papers (original and reviews) thematically connected to the scope of this Special Issue. We are particularly, but not exclusively, interested in papers focused on the effects of policies, community programs, and the implementation of new practices on cancer prevention. We believe that *Cancers* is an ideal platform to exchange perspectives and to present results of studies on cancer prevention and epidemiology.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us